Microviable Therapeutics joins the European Microbiome Innovation for Health (EMIH)
EMIH is an independent European coalition, a public and private initiative, and a non-profit organization aiming to ensure that microbiome-based medical innovations become a public health priority in the European Union. EMIH represents innovative European stakeholders dedicated to advancing the microbiome industry to promote medical innovation in the European Union. EMIH gathers more than 25 (and growing) key private and public players supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
Microviable has join the organization as a drug developer based on our activity as a biotech company developing novel biological medicines based on the microbiota. Moreover, Claudio Hidalgo will join the Board of Directors of EMIH together with other leaders contributing actively into the management of this European organization.
Claudio Hidalgo, CEO at Microviable: I foresee the EMIH as a key organization that represents the scientific leaders and entrepreneurs developing next generation microbiome products to address unmet challenges in human health. As developers of novel microbiome biological medicines, Microviable is well considered to be part of the organization and will actively contribute to it.
I truly believe that the union of the different companies in one organization will generate a solid entity enabling to represent the microbiome sector protecting the interest of our industry, and lead the conversations with the regulatory agencies to establish a comprehensive framework, while pushing for novel medicines based on the microbiome that can benefit the European heath care. Noteworthy, the union of the companies under EMIH will strengthen the relationship between each of the members for the benefit of our industry.
